HSP

Healthscope (HSP)

Wed, 19/11/2008 - 16:45

Stock Code

HSP

Stock Exchange

Australian Securities Exchange

Healthscope (HSP) is one of the major healthcare services provider in Australia. The Company owns and operates a portfolio of around 45 medical/surgical, rehabilitation and psychiatric hospitals. Healthscope is also engaged in the provision of pathology services across Australia, New Zealand, Singapore and Malaysia. Healthscope listed on the Australian Stock Exchange on May 4, 1994. In December 2004, Healthscope acquired Gribbles, which helped it in achieving a significant position in the pathology industry.

Top 200 Australian Companies Best 10 Gainers


Here are the Top 200 Australian Companies top 10 stocks which gained the most percentage points of company value on the share market, the Australian Securities Exchange (ASX) this 29th week of 2010 (last week):

The Best 3 Companies of the Week


Paladin Energy, (PDN), a company which is mainly involved in the acquisition and development of uranium projects in Australia and Africa had the best performing stocks of the week in ASX100 with a gain of 10.2 percent or 38 cents closing the week at $4.08.

Healthscope Receives $1.7 Billion Worth Takeover Bid


In a recent statement, Healthscope (HSP), one of the leading Australia based healthcare service providers that owns and operates around 45 medical/surgical, rehabilitation and psychiatric hospitals declared that it has received an indicative, non-binding and confidential takeover proposal from a private equity consortium. The bid worth as much as $1.74 billion, asking for $5.50 for each Healthscope share.

Reporting Season Final Update (March 2007)


Last week, global markets stumbled following reports that China was looking to impose controls to curb its rapidly growing economy and concerns that a soft landing for the US economy may be more difficult than first thought. In the background, the Australian reporting season continued its final week, here are analyst Macquarie Research Equities (MRE) observations and thoughts. The HY December 2006 aggregate earnings reported for the market printed 1.5 percentage points below analyst expectations versus those held at the start of this reporting season.

Healthscope (HSP) Shares Tip


Healthscope (HSP) have a 12 month share price target of $6.05 and an Outperform stock recommendation from shares analyst Macquarie Research Equities (MRE). MRE also note that current political and economic trends would generally point toward sustained industry health for the foreseeable future. The stock has drifted 6 cents lower despite announcing that they will build a new 142 bed hospital in North Western Sydney at a cost of $52m. Macquarie Research Equities (MRE) estimate that the hospital will not make a contribution to earnings until FY12 even under optimistic guidelines. MRE believe this announcement is more relevant for the implications of the industry dynamics. Greenfield hospital developments have been rare since the late 1990’s, when a number of projects almost crippled hospital groups. MRE highlight Westmead Private hospital which took Alpha Healthcare to the brink of collapse. This however was later acquired by Ramsay (RHC). The most recent Greenfield project of size was the new Epworth Hospital in Melbourne which is also struggling under the weight of its fixed costs. MRE have an Outperform recommendation on HSP.

Healthscope (HSP) Stock Recommendation


Macquarie Research Equities have reiterated their Outperform recommendation for the Healthscope (HSP) stock with a 12 month share price target of $5.15. They have commented that the company result was better than expected and that their margins were better than expected. HSP achieved a 14.3 percent in underlying EBITDA margins in 2H06, which is typically a seasonally weak half in private hospital operations.

Healthscope (HSP) Recommendation by MRE


Is this an opportunity? The way I look at it is that this opportunity has a medium risk to it - you need to track this one of you want to participate. Their 12 month price target is $6.55 which is an upside of almost 50% above yesterday's closing price...

"The second largest private hospital group in Australia plunged to an 8 month low of $4.38 after announcing that weak pathology earnings in NSW and Victoria would result in the company’s human pathology earnings falling below that forecast in their December 2004 prospectus."

Syndicate content